- Press Release Medication can help prevent HIV among IDU
- Press Release Know Hepatitis B: Targeted CDC campaign promotes testing
- Press Release HIV campaign for Latino gay & bisexual men
Study Shows That A Daily Dose of HIV Medication Reduces Infection Risk among People Who Inject Drugs
A daily dose of a medication used to treat HIV infection – a prevention strategy known as pre-exposure prophylaxis (PrEP) - reduced the risk of infection among people who inject drugs by 49 percent according to a new study announced today. Those who took the medication most consistently had even higher levels of protection – in this group, risk was reduced by over 70 percent.
The findings were published online today in the Lancet. CDC also published interim guidance for providers who wish to prescribe PrEP to people who inject drugs in this week’s Morbidity and Mortality Weekly Report.
To help inform your stories on this groundbreaking research, please find below key materials outlining the trial’s results, as well as additional background information on PrEP. If you are a reporter and need a copy of the Lancet paper, please contact the NCHHSTP media team at NCHHSTPMediaTeam@cdc.gov.
Primary Materials
- Press Release: Study Finds First Evidence that PrEP Can Reduce HIV Risk Among People Who Inject Drugs
- Fact Sheet: Bangkok Tenofovir Study: PrEP for HIV Prevention Among People Who Inject Drugs
- Interim Guidance: Update to Interim Guidance for Pre-Exposure Prophylaxis (PrEP) for the Prevention of HIV Infection: PrEP for Injecting Drug Users
- Downloadable Photos for Media Use/Reprint
Related Materials
News Releases and Announcements
- June 12, 2013 - New CDC Campaign: Know Hepatitis B
Today, CDC launched Know Hepatitis B, the first national multilingual, multi-year communications campaign to increase testing for hepatitis B among Asian Americans and Pacific Islanders.
While making up only less than 5 percent of the U.S. population, Asian Americans and Pacific Islanders account for more than half of the 1.2 million Americans estimated to be living with chronic hepatitis B. Yet most of those living with the disease don’t know it because they haven’t been tested. Left undiagnosed and untreated, hepatitis B can cause serious liver damage and even death.
To assist with your coverage of this new important campaign, please find below various media resources.
Primary Materials- Press Release: CDC launches first national campaign to increase hepatitis B testing among Asian Americans and Pacific Islanders
- Fact Sheet: Know Hepatitis B – Combating One of the Most Severe Health Disparities Facing Asian Americans and Pacific Islanders
Related Materials- Downloadable Campaign Images for Media Use/Reprint
- Campaign Website: Know Hepatitis B
- Archive Previous Press Releases, Fact Sheets and Statements
Disease Information
- HIV/AIDS CDC's comprehensive Web site on HIV/AIDS
- STDs CDC’s site covering BV, Chlamydia, Herpes, HPV, Gonorrhea, PID, Syphilis and Trichomoniasis
- Tuberculosis CDC’s site offering a wide-range of information on TB
- Viral Hepatitis CDC’s site providing information on Hepatitis A, B, C, D and E
NCHHSTP Experts
- Gail Bolan, MD: Director, Sexually Transmitted Disease Prevention Program
- RADM Kenneth G. Castro, MD: Assistant Surgeon General, U.S. Public Health Service; Director, Tuberculosis Elimination Program
- Jonathan Mermin, MD, MPH: Director, HIV/AIDS Prevention Program
- John Ward, MD: Director, Viral Hepatitis Program
- Howell Wechsler, EdD, MPH: Director, Division of Adolescent and School Health
NCHHSTP
CDC's National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP) is responsible for public health surveillance, prevention research, and programs to prevent and control HIV and AIDS, other STDs, viral hepatitis, and TB. NCHHSTP staff work in collaboration with governmental and nongovernmental partners at the community, state, national, and international levels.
